South Korea's HK inno.N Targets Cell Therapy, Vaccine Expansion Following $500m IPO
Record High Subscriptions From Institutional Investors
South Korean pharma HK inno.N’s $500m IPO has drawn strong interest with subscriptions from institutional investors marking a record high. The IPO should help it speed up development of cell and gene therapies and beef up its vaccines business.
You may also be interested in...
Korean bioventure ViGenCell successfully completes an IPO on the Kosdaq market with strong subscription rates from investors, reflecting the continued keen interest in biopharma shares in South Korea this year.
The acquisition of mid-size South Korean pharma firm CJ HealthCare is set to boost Kolmar Korea's pharma business, enabling the cosmetics and pharma company to transform into a larger and more integrated healthcare firm.
As the global biopharma industry attempts to understand the implications of the US Inflation Reduction Act, South Korea's biopharma industry is pressing its government to come up with "bold and rapid" additional measures to reduce the possible negative impact of the legislation and other US policies with international implications, and to support the sector amid generally rising global competition.